-
Je něco špatně v tomto záznamu ?
EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study
KK. Ray, B. Molemans, WM. Schoonen, P. Giovas, S. Bray, G. Kiru, J. Murphy, M. Banach, S. De Servi, D. Gaita, I. Gouni-Berthold, GK. Hovingh, JJ. Jozwiak, JW. Jukema, RG. Kiss, S. Kownator, HK. Iversen, V. Maher, L. Masana, A. Parkhomenko, A....
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, pozorovací studie, práce podpořená grantem
PubMed
33580789
DOI
10.1093/eurjpc/zwaa047
Knihovny.cz E-zdroje
- MeSH
- anticholesteremika * škodlivé účinky MeSH
- biologické markery MeSH
- dyslipidemie * farmakoterapie MeSH
- kardiovaskulární nemoci * diagnóza epidemiologie prevence a kontrola MeSH
- LDL-cholesterol MeSH
- lidé MeSH
- primární zdravotní péče MeSH
- proproteinkonvertasa subtilisin/kexin typu 9 MeSH
- průřezové studie MeSH
- rizikové faktory MeSH
- statiny * terapeutické užití MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
- práce podpořená grantem MeSH
AIMS: To provide contemporary data on the implementation of European guideline recommendations for lipid-lowering therapies (LLTs) across different settings and populations and how this impacts low-density lipoprotein cholesterol (LDL-C) goal achievement. METHODS AND RESULTS: An 18 country, cross-sectional, observational study of patients prescribed LLT for primary or secondary prevention in primary or secondary care across Europe. Between June 2017 and November 2018, data were collected at a single visit, including LLT in the preceding 12 months and most recent LDL-C. Primary outcome was the achievement of risk-based 2016 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) LDL-C goal while receiving stabilized LLT; 2019 goal achievement was also assessed. Overall, 5888 patients (3000 primary and 2888 secondary prevention patients) were enrolled; 54% [95% confidence interval (CI) 52-56] achieved their risk-based 2016 goal and 33% (95% CI 32-35) achieved their risk-based 2019 goal. High-intensity statin monotherapy was used in 20% and 38% of very high-risk primary and secondary prevention patients, respectively. Corresponding 2016 goal attainment was 22% and 45% (17% and 22% for 2019 goals) for very high-risk primary and secondary prevention patients, respectively. Use of moderate-high-intensity statins in combination with ezetimibe (9%), or any LLT with PCSK9 inhibitors (1%), was low; corresponding 2016 and 2019 goal attainment was 53% and 20% (ezetimibe combination), and 67% and 58% (PCSK9i combination). CONCLUSION: Gaps between clinical guidelines and clinical practice for lipid management across Europe persist, which will be exacerbated by the 2019 guidelines. Even with optimized statins, greater utilization of non-statin LLT is likely needed to reduce these gaps for patients at highest risk.
Advanced Lipid Management and Research Centre Tallaght University Hospital Dublin 24 Ireland
Amgen Hellas 4 Gravias Street Maroussi 15125 Athens Greece
Amgen Inc 1 Amgen Center Drive Thousand Oaks CA 91320 USA
Cardiology Department Sahlgrenska University Hospital 413 45 Gothenburg Sweden
Cardiovascular Research Centre University of Zielona Góra 65 417 Zielona Góra Poland
Centre Cardiologique et Vasculaire 36 Route de la Briquerie 57100 Thionville France
Charles University Prague 116 36 Czech Republic
Cliniques Universitaires Saint Luc Avenue Hippocrate 10 1200 Brussels Belgium
Department of Family Medicine and Public Health Faculty of Medicine University of Opole Opole Poland
Department of Molecular and Clinical Medicine University of Gothenburg 405 30 Gothenburg Sweden
Emergency Cardiology Department Institute of Cardiology Kiev Ukraine
Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark
Global Biostatistical Science Amgen Ltd 240 Cambridge Science Park Milton Road Cambridge CB4 0WD UK
Hungarian Army Medical Center Budapest 1134 Hungary
Imperial Clinical Trials Unit Imperial College London Stadium House 68 Wood Lane London W12 7RH UK
Imperial Hospitals NHS Trust London W12 0HS UK
IRCCS MultiMedica Via Milanese 300 20099 Sesto San Giovanni Milan Italy
Krankenhaus Barmherzige Schwestern Linz Seilerstðtte 4 4010 Seilerstätte 4 4010 Linz Austria
Leiden University Medical Center Albinusdreef 2 2333 ZA Leiden Netherlands
National and Kapodistrian University of Athens Medical School Athens Greece
Polish Mother's Memorial Hospital Research Institute 93 338 Lodz Poland
Polyclinic for Endocrinology Diabetes and Preventive Medicine Kerpener Str 62 50937 Cologne Germany
Slovak Medical University 831 01 Bratislava Slovakia
Trinity College Dublin Dublin 2 Ireland
Universitat Rovira i Virgili IISPV CIBERDEM Saint Joan University Hospital Reus Spain
University of Amsterdam Faculty of Medicine Amsterdam the Netherlands
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22019671
- 003
- CZ-PrNML
- 005
- 20220804135904.0
- 007
- ta
- 008
- 220720s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/eurjpc/zwaa047 $2 doi
- 035 __
- $a (PubMed)33580789
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Ray, Kausik K $u Imperial Centre for Cardiovascular Disease Prevention and Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK
- 245 10
- $a EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study / $c KK. Ray, B. Molemans, WM. Schoonen, P. Giovas, S. Bray, G. Kiru, J. Murphy, M. Banach, S. De Servi, D. Gaita, I. Gouni-Berthold, GK. Hovingh, JJ. Jozwiak, JW. Jukema, RG. Kiss, S. Kownator, HK. Iversen, V. Maher, L. Masana, A. Parkhomenko, A. Peeters, P. Clifford, K. Raslova, P. Siostrzonek, S. Romeo, D. Tousoulis, C. Vlachopoulos, M. Vrablik, AL. Catapano, NR. Poulter, DA VINCI study
- 520 9_
- $a AIMS: To provide contemporary data on the implementation of European guideline recommendations for lipid-lowering therapies (LLTs) across different settings and populations and how this impacts low-density lipoprotein cholesterol (LDL-C) goal achievement. METHODS AND RESULTS: An 18 country, cross-sectional, observational study of patients prescribed LLT for primary or secondary prevention in primary or secondary care across Europe. Between June 2017 and November 2018, data were collected at a single visit, including LLT in the preceding 12 months and most recent LDL-C. Primary outcome was the achievement of risk-based 2016 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) LDL-C goal while receiving stabilized LLT; 2019 goal achievement was also assessed. Overall, 5888 patients (3000 primary and 2888 secondary prevention patients) were enrolled; 54% [95% confidence interval (CI) 52-56] achieved their risk-based 2016 goal and 33% (95% CI 32-35) achieved their risk-based 2019 goal. High-intensity statin monotherapy was used in 20% and 38% of very high-risk primary and secondary prevention patients, respectively. Corresponding 2016 goal attainment was 22% and 45% (17% and 22% for 2019 goals) for very high-risk primary and secondary prevention patients, respectively. Use of moderate-high-intensity statins in combination with ezetimibe (9%), or any LLT with PCSK9 inhibitors (1%), was low; corresponding 2016 and 2019 goal attainment was 53% and 20% (ezetimibe combination), and 67% and 58% (PCSK9i combination). CONCLUSION: Gaps between clinical guidelines and clinical practice for lipid management across Europe persist, which will be exacerbated by the 2019 guidelines. Even with optimized statins, greater utilization of non-statin LLT is likely needed to reduce these gaps for patients at highest risk.
- 650 12
- $a anticholesteremika $x škodlivé účinky $7 D000924
- 650 _2
- $a biologické markery $7 D015415
- 650 12
- $a kardiovaskulární nemoci $x diagnóza $x epidemiologie $x prevence a kontrola $7 D002318
- 650 _2
- $a LDL-cholesterol $7 D008078
- 650 _2
- $a průřezové studie $7 D003430
- 650 12
- $a dyslipidemie $x farmakoterapie $7 D050171
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a statiny $x terapeutické užití $7 D019161
- 650 _2
- $a primární zdravotní péče $7 D011320
- 650 _2
- $a proproteinkonvertasa subtilisin/kexin typu 9 $7 D000071449
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Molemans, Bart $u Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA 91320, USA
- 700 1_
- $a Schoonen, W Marieke $u Center for Observational Research (CfOR), Amgen Ltd, 1 Uxbridge Business Park Sanderson Road, Uxbridge, UB8 1DH, UK
- 700 1_
- $a Giovas, Periklis $u Amgen Hellas, 4 Gravias Street, Maroussi, 15125, Athens, Greece
- 700 1_
- $a Bray, Sarah $u Global Biostatistical Science, Amgen Ltd, 240 Cambridge Science Park, Milton Road, Cambridge, CB4 0WD, UK
- 700 1_
- $a Kiru, Gaia $u Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK
- 700 1_
- $a Murphy, Jennifer $u Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK
- 700 1_
- $a Banach, Maciej $u Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, 90-419 Lodz, Poland $u Polish Mother's Memorial Hospital - Research Institute (PMMHRI), 93-338 Lodz, Poland $u Cardiovascular Research Centre, University of Zielona Góra, 65-417 Zielona Góra, Poland
- 700 1_
- $a De Servi, Stefano $u IRCCS MultiMedica, Via Milanese, 300, 20099 Sesto San Giovanni, Milan, Italy
- 700 1_
- $a Gaita, Dan $u Institutul de Boli Cardiovasculare, Fundatia Cardioprevent, Universitatea de Medicina si Farmacie Victor Babes din Timisoara, Timişoara 300041, Romania
- 700 1_
- $a Gouni-Berthold, Ioanna $u Polyclinic for Endocrinology, Diabetes and Preventive Medicine, Kerpener Str. 62, 50937 Cologne, Germany
- 700 1_
- $a Hovingh, G Kees $u University of Amsterdam Faculty of Medicine, Amsterdam, the Netherlands
- 700 1_
- $a Jozwiak, Jacek J $u Department of Family Medicine and Public Health, Faculty of Medicine, University of Opole, Opole, Poland
- 700 1_
- $a Jukema, J Wouter $u Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, Netherlands
- 700 1_
- $a Kiss, Robert Gabor $u Hungarian Army Medical Center, Budapest, 1134, Hungary
- 700 1_
- $a Kownator, Serge $u Centre Cardiologique et Vasculaire, 36 Route de la Briquerie, 57100, Thionville, France
- 700 1_
- $a Iversen, Helle K $u Stroke Centre Rigshospitalet, Department of Neurology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark $u Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- 700 1_
- $a Maher, Vincent $u Trinity College Dublin, Dublin 2, Ireland $u Advanced Lipid Management and Research Centre, Tallaght University Hospital, Dublin 24, Ireland
- 700 1_
- $a Masana, Luis $u Universitat Rovira i Virgili, IISPV, CIBERDEM, Saint Joan University Hospital, Reus, Spain
- 700 1_
- $a Parkhomenko, Alexander $u Emergency Cardiology Department, Institute of Cardiology, Kiev, Ukraine
- 700 1_
- $a Peeters, André $u Cliniques Universitaires Saint Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium
- 700 1_
- $a Clifford, Piers $u Imperial Hospitals NHS Trust (Hammersmith Campus), London W12 0HS, UK
- 700 1_
- $a Raslova, Katarina $u Slovak Medical University, 831 01 Bratislava, Slovakia
- 700 1_
- $a Siostrzonek, Peter $u Krankenhaus Barmherzige Schwestern Linz, Seilerstðtte 4, 4010 Seilerstätte 4, 4010 Linz, Austria $1 https://orcid.org/0000000248984606
- 700 1_
- $a Romeo, Stefano $u Department of Molecular and Clinical Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden $u Clinical Nutrition, Department of Medical and Surgical Sciences, Magna Graecia University, 88100 Catanzaro, Italy $u Cardiology Department, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden
- 700 1_
- $a Tousoulis, Dimitrios $u National and Kapodistrian University of Athens, Medical School, Athens, Greece
- 700 1_
- $a Vlachopoulos, Charalambos $u National and Kapodistrian University of Athens, Medical School, Athens, Greece
- 700 1_
- $a Vrablik, Michal $u Charles University, Prague, 116 36 Czech Republic
- 700 1_
- $a Catapano, Alberico L $u Department of Pharmacological and Biomolecular Sciences, IRCCS Multimedica, Via Milanese, 300, 20099 Sesto San Giovanni, Milan, Italy
- 700 1_
- $a Poulter, Neil R $u Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK
- 710 2_
- $a DA VINCI study
- 773 0_
- $w MED00188754 $t European journal of preventive cardiology $x 2047-4881 $g Roč. 28, č. 11 (2021), s. 1279-1289
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33580789 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804135857 $b ABA008
- 999 __
- $a ok $b bmc $g 1823043 $s 1170914
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 28 $c 11 $d 1279-1289 $e 20210920 $i 2047-4881 $m European journal of preventive cardiology $n Eur J Prev Cardiol $x MED00188754
- LZP __
- $a Pubmed-20220720
